Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

被引：1

作者：

Nastoupil, Loretta J. ^{[1
]}

Andersen, Clark R. ^{[1
]}

Ayers, Amy ^{[1
]}

Wang, Yucai ^{[2
]}

Habermann, Thomas M. ^{[2
]}

Chihara, Dai ^{[1
]}

Kahl, Brad S. ^{[3
]}

Link, Brian K. ^{[4
]}

Cohen, Jonathon B. ^{[5
]}

Martin, Peter ^{[6
]}

Lossos, Izidore S. ^{[7
]}

Casulo, Carla ^{[8
]}

Lin, Ruitao ^{[1
]}

Li, Ziyi ^{[1
]}

Larson, Melissa C. ^{[2
]}

Maurer, Matthew J. ^{[2
]}

Huynh, Lynn ^{[9
]}

Gao, Chi ^{[9
]}

Ramasubramanian, Ramya ^{[9
]}

Sheng, Mei ^{[9
]}

Mutebi, Alex ^{[10
]}

Wang, Tongsheng ^{[10
]}

Jun, Monika ^{[10
]}

Wang, Anthony ^{[11
]}

Kamalakar, Rajesh ^{[11
]}

Kalsekar, Anupama ^{[10
]}

Cerhan, James R. ^{[2
]}

Flowers, Christopher R. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Mayo Clin, Rochester, MN USA

[3] Washington Univ, Sch Med St Louis, St Louis, MO USA

[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA

[5] Emory Univ, Atlanta, GA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Miami Hlth Syst, Miami, FL USA

[8] Univ Rochester, Med Ctr, Rochester, NY USA

[9] Anal Grp Inc, Boston, MA USA

[10] Genmab, Princeton, NJ USA

[11] AbbVie Inc, Chicago, IL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174497

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
Nastoupil, Loretta J.
Andersen, Clark
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Ayyappan, Sabarish
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Casulo, Carla
Lin, Ruitao
Li, Ziyi
Larson, Melissa A.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Duh, Mei Sheng
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S442 - S443
[2] GENERATING HEALTH-STATE UTILITY VALUES IN PATIENTS TREATED WITH SECOND-LINE SYSTEMIC THERAPY FOR RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)
Soare, I. A.
Little, M.
Klijn, S. L.
Elsada, A.
Gibson, A.
Liu, F. F.
Becker, F.
VALUE IN HEALTH, 2023, 26 (12) : S463 - S463
[3] Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Nastoupil, Loretta J.
Andersen, Clark R.
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Koff, Jean L.
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Stanchina, Michele
Haddadi, Sara
Casulo, Carla
Ayyappan, Sabarish
Lin, Ruitao
Li, Ziyi
Larson, Melissa A.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Duh, Mei Sheng
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04):
[4] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lee, Dasom
Kambhampati, Swetha
Bobillo, Maria Silvina Odstrcil
Adedokun, Babatunde
Shadman, Mazyar
Olson, Amanda L.
Herrera, Alex F.
Lee, Catherine J.
Jacobson, Caron A.
Bye, Matthew
Hamadani, Mehdi
Kim, Soyoung
Dahiya, Saurabh
Hu, Zhen-Huan
Speth, Kelly
To, Christina
Mirjah, Debbie L.
Best, Timothy
Locke, Frederick L.
Ahmed, Nausheen
Tees, Michael T.
Pasquini, Marcelo C.
Ahmed, Sairah
BLOOD, 2024, 144 : 527 - 528
[5] Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
Lunning, Matthew A.
Wang, Hai-Lin
Hu, Zhen-Huan
Locke, Frederick L.
Siddiqi, Tanya
Jacobson, Caron A.
Ahmed, Sairah
Miklos, David B.
Lin, Yi
Hill, Brian T.
Ghobadi, Armin
Neelapu, Sattva S.
Westin, Jason
Miao, Harry
Shahani, Shilpa
Patel, Anik R.
Spooner, Clare
Fu, Christine
Xu, Hairong
Pasquini, Marcelo C.
BLOOD, 2022, 140 : 1852 - 1855
[6] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
Deger, K.
Oniangue-Ndza, C.
Elsada, A.
Litkiewicz, M.
Villalobos, Franco C.
Sorensen, S.
VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
[7] Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Choe, Jee H.
Abdel-Azim, Hisham
Padula, William, V
Abou-El-Enein, Mohamed
JAMA NETWORK OPEN, 2022, 5 (12)
[8] Salvage therapy R-DAOx in patients with relapsed or refractory diffuse large B-CELL lymphoma
Mappa, S.
Rigacci, L.
Nassi, L.
Puccini, B.
Alterini, R.
Carrai, V.
Bernardi, F.
Bosi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
[9] The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Purdum, Anna
Johnson, Jonathan
Bonagura, Anthony
Nyamutswa, Liliosa
Elliott, Caitlin
Lal, Lincy S.
BLOOD, 2020, 136
[10] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Topp, Max S.
van Meerten, Tom
Wermke, Martin
Lugtenburg, Elly J.
Minnema, Monique C.
Song, Kevin W.
Thieblemont, Catherine
Jiang, Yizhou
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →